Type of information: Private placement
Company: RegenXBio (USA - MD)
Amount: $75.85 million
Funding type: private placement
Others: * On March 21, 2017, Regenxbio announced the pricing of an underwritten public offering of 3,700,000 shares of its common stock at the price of $20.50 per share before underwriting discounts and commissions. The gross proceeds from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be approximately $75.85 million. This offering is expected to close on March 27, 2017, subject to customary closing conditions. The company has granted the underwriters a 30-day option to purchase an additional 555,000 shares of common stock at the public offering price, less underwriting discounts and commissions. Morgan Stanley, BofA Merrill Lynch and Piper Jaffray & Co. are acting as joint book-running managers. Chardan Capital Markets, is acting as co-manager of the offering. * On March 21, 2017, Regenxbio announced that it intends to offer and sell, subject to market conditions, $75,000,000 of its common stock in an underwritten public offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering.
Therapeutic area: Rare diseases - Genetic diseases